Research supported by Horizon Europe plays a central role in strengthening Europe’s scientific excellence, technological leadership, and capacity to address major societal challenges. As the European Union’s main research and innovation framework programme, Horizon Europe promotes collaboration between universities, research institutes, industry, and healthcare organizations across Europe and beyond. By funding ambitious and interdisciplinary projects, the programme accelerates the development of advanced technologies, supports the translation of scientific discoveries into practical applications, and fosters innovation that benefits society. In fields such as healthcare and cancer research, Horizon Europe enables the creation of novel diagnostic and therapeutic approaches, contributing to improved patient outcomes and reinforcing Europe’s global leadership in science and technology.

A fitting inspirational quotation is from Robert Schuman, one of the founding figures of European integration:

“World peace cannot be safeguarded without the making of creative efforts proportionate to the dangers which threaten it.”

Although originally referring to European cooperation, this statement strongly resonates with the spirit of Horizon Europe, where collaborative scientific research and innovation represent the “creative efforts” needed to address today’s global challenges—from health and cancer to climate and sustainability.

Research funded through Horizon Europe plays a strategic role in strengthening Europe’s capacity to translate scientific discovery into real societal impact. By fostering collaboration among universities, research institutes, hospitals, and industry, the programme supports interdisciplinary projects that move innovations from laboratory research toward clinical and technological applications.

A clear example can be found in advanced biomedical technologies for cancer care. Modern real-time optical biopsy approaches—such as Raman Spectroscopy, Coherent Anti-Stokes Raman Scattering, Optical Coherence Tomography, and Confocal Laser Endomicroscopy—allow clinicians to visualize tissue structure and biochemical composition directly during endoscopic procedures. These techniques can significantly reduce diagnostic delays and minimize the need for invasive biopsies by providing near real-time information on tumor presence and margins.

At the same time, emerging treatment modalities such as Cold Atmospheric Plasma offer innovative therapeutic opportunities. Cold plasma generates reactive oxygen and nitrogen species that can selectively damage cancer cells, induce apoptosis, and potentially stimulate anti-tumor immune responses. Because plasma sources can be miniaturized and integrated into medical devices, they are particularly attractive for localized and minimally invasive treatments.

The real innovation emerges when these diagnostic and therapeutic technologies are integrated into a single platform. A system combining optical biopsy with plasma delivery could enable a closed-loop clinical workflow: first detecting suspicious tissue in real time, then precisely targeting it with plasma treatment, and finally reassessing the treated area using the same optical modalities. Such integration could improve treatment precision, reduce surgical margins, and shorten clinical procedures.

From a broader perspective, programmes such as Horizon Europe are essential because they provide the long-term, collaborative framework required to develop complex technologies of this kind. Projects often involve physicists, engineers, clinicians, and industry partners working together to transform fundamental research into clinically deployable solutions. In this way, European research initiatives help accelerate innovation in healthcare while strengthening Europe’s leadership in advanced biomedical technologies and improving patient outcomes. 

Conclusions and key considerations

The discussion highlights how the convergence of advanced science and enabling technologies can transform the future of cancer care. Cutting-edge optical techniques such as Raman Spectroscopy, Coherent Anti-Stokes Raman Scattering, Optical Coherence Tomography, and Confocal Laser Endomicroscopy are making real-time optical biopsyincreasingly feasible, allowing clinicians to observe the structural and biochemical signatures of tumors directly during medical procedures. At the same time, innovative therapeutic strategies such as Cold Atmospheric Plasma open new possibilities for localized, minimally invasive cancer treatment by selectively targeting malignant cells.

The true potential of these innovations emerges when diagnosis and therapy are combined into a single, intelligent platform capable of detecting, treating, and monitoring disease in real time. Such integrated approaches represent a new paradigm in oncology—one in which precision, speed, and personalization become central elements of patient care.

Support from collaborative research frameworks such as Horizon Europe is essential to turn these visions into reality. By bringing together scientists, engineers, clinicians, and industry partners across Europe, these initiatives create the environment where ambitious ideas can evolve into practical medical solutions.

Looking ahead, the integration of advanced optical diagnostics with innovative therapeutic technologies points toward a future where cancer detection is earlier, treatments are more targeted, and clinical procedures are less invasive. Continued investment in interdisciplinary research will not only expand scientific knowledge but also translate that knowledge into tangible benefits for patients, demonstrating how visionary science and technology can work together to reshape the future of medicine.